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KAJIAN EPIDIOMOLOGI DAN PENILAIAN KLINIKAL TUBERKULOSIS 
BESERTA DENGAN STATUS KO-MORBIDITI DI KALANGAN POPULASI 
UMUM DAN PENGHUNI PENJARA DI MALAYSIA 
ABSTRAK 
Ancaman penyakit tuberkulosis (TB) menunjukkan peningkatan yang ketara 
dengan ancaman kematian kepada kombinasi TB dengan status komobiditi seperti 
Virus Kurang Daya Tahan Penyakit (HIV)-Sindrom Daya Kurang Tahan Penyakit 
(AIDS), diabetes mellitus (DM) dan penyakit hepatitis. Melihat secara global 
populasi pesakit di penjara adalah berisiko tinggi mendapat penyakit ini berbanding 
populasi umum. Walaubagaimana pun tidak terdapat data yang mencukupi 
berkenaan jenis-jenis TB beserta dengan komorbiditinya di Malaysia. Tujuan kajian 
ini adalah untuk mengumpul data yang komprehensif berkenaan epidimiologi dan 
outcome dari rawatan TB sendiri dengan komorbiditi di hospital dan penjara di empat 
negeri di Malaysia. i.e Pulau Pinang, Sabah, Sarawak dan Selangor. Kajian 
retrospektif telah dijalankan dengan mengumpul data dari 9337 pesakit, dari rekod 
pesakit yang terdapat di hospital dan penjara dan juga satu kajian prospektif secara 
sesi soal-jawab, dari Januari 2006 sehingga Disember 2008. Daripada 9337 pesakit 
terpilih, 405 adalah dari penjara dan selebihnya adalah dari populasi umum. Data 
yang diperoleh telah dianalisa menggunakan perisian "Statistical Package for the 
Social Sciences" (SPSS). Jumlah tertinggi pesakit adalah dari negeri Sabah. Dari 
jurnlah keseluruhan pesakit, majoriti pesakit (7781) menghidapi TB pulmonary 
(PTB). Daripada 1222 kes jangkitan extrapulmonary tuberculosis (EPTB), 
kebanyakannya adalah kes-kes lymphadenitis TB [325 (26.6%)]. Terdapat 8159 
(87.4%) pesakit kes bam didaftar dan 675 (7.2%) adalah kes relaps (berulang). 
xxi 
Terdapat 6650 (71.2%) pesakt mempunyai sputum smear positif. Apabila faktor 
sosio-demografik dikaitkan dengan prevelans dari ketiga-tiga jenis TB di dapati 
kejadian adalah lebih tinggi di kalangan lelaki, tidak berkahwin, bangsa Melayu dan 
berumur diantara 31 - 50 tahun. Lebih daripada itu, kejadian PTB, EPTB beserta 
komorbiditi lebih tingi secara signifikan teijadi di populasi bandar. Meminum 
alkohol telah dikenalpasti sebagai faktor risiko untuk kombinasi PTB dengan EPTB. 
Prevalens TB-Hepatitis dan TB-HIV adalah lebih tinggi kepada lelaki belum 
berkahwin, tidak bekeija dan perokok dari kalangan bangsa Melayu, sementara TB-
DM lebih tinggi di dalam bangsa Cina. Golongan yang berumur 56-65 tahun adalah 
lebih terdedah kepada TB-DM, manakala TB-HIV dan TB-hepatitis adalah lebih 
kepada golongan umur yang aktif secara seksual. Pesakit dengan DM mempunyai 
insiden lebih tinggi mendapat PTB (87.5%) dan pesakit dengan HIV/AIDS 
mempunyai insiden lebih tinggi mendapat EPTB (26.1 %) dan PTB bersama EPTB 
(6.1%). Kadar insiden TB di penjara adalah 440/100,000 populasi. Penjara Selangor 
mencatat insiden yang tertinggi (755/100,000). Kebanyakan pesakit (78.9%) 
mengatakan batuk adalah simptom yang dihadapi. Ujian sensitiviti kultur adalah 
lebih pasti untuk diagnosis yang mana 70.6% pesakit memberi respond positif. 
Daripada 9337 pesakit, 7241 (77.6%) pesakit telah beijaya dirawat. Kejayaan 
rawatan adalah lebih tinggi dikalangan pesakit PTB (79.5%). Apabila TB-DM, TB-
HIV/AIDS DAN TB-Hepatitis di nilai, 73.3%, 68.6% dan75.4% pesakit betjaya 
dirawat masing masing. Kadar mortaliti adalah lebih tinggi (23.8%) di kalangan 
kurnpulan pesakit TB-DM-HIV. Faktor risiko yang dikenalpasti menyurnbang 
kepada kadar mortaliti yang tinggi dalam kumpulan pesakit ini adalah usia yang 
meningkat, meminum alkohol dan bangsa Cina. 
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EPIDEMIOLOGICAL I CLINICAL EVALUATION OF TUBERCULOSIS 
ALONG WITH ITS CO-MORBID STATUS IN GENERAL POPULATION 
AND IN PRISONS IN MALAYSIA 
ABSTRACT 
The threat of tuberculosis (TB) seemed to have become increasingly looming 
with the fatal combination of co-morbid conditions like human immunodeficiency 
virus (HIV)-acquired immune deficiency syndrome (AIDS), diabetes mellitus (DM) 
and hepatitis. Globally, prison population is at a higher risk to acquire these diseases 
as compared to general population. However, there is no substantial data concerning 
the different types of TB and its co-morbidities in Malaysia. The aim of the present 
study was to obtain a comprehensive data pertaining to the epidemiology and clinical 
evaluation of TB alone and with co-morbidities in the hospitals and prisons of the 
four states of Malaysia i.e. Penang, Sabat., Sarawak and Selangor. A retrospective 
study was performed by collecting data of 9337 patients, from the patient records 
available at the hospitals and prisons and a prospective study was also conducted 
through direct question-answer session from January 2006, to December 2008. Out of 
the total selected 9337 patients, 405 were from the prisons and the remaining were 
from the general population. Data obtained was a.."lalyzed with Statistical Package for 
the Social Sciences (SPSS) software. The highest number of patients was from Sabah 
state. Among the total selected patients, majority of them (7781) had pulmonary 
tuberculosis (PTB). Out of the total number of 1222 patients with confirmed extra-
pulmonary tuberculosis (EPTB), majority were suffering from lymphadenitis TB [325 
(26.6%)]. Among the total number of cases, 8159 (87.4%) were newly registered and 
675 (7.2%) were relapsed cases. Of the total number of patients 6650 (71.2%) were 
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found to be sputum smear positive. When socio-demographic factors were related to 
the prevalence of the three types of TB the occurrence was higher among the male 
population, unmarried, Malay race and the age group 31 - 50 yr. Furthermore, the 
occurrence of PTB, EPTB along with co-morbidity were significantly higher in urban 
population. Alcohol consumption was identified as a risk factor for PTB with EPTB 
combination. The prevalence of TB-Hepatitis and TB-HIV was higher in unmarried 
and unemployed male smokers of Malay race, whereas tuberculosis-Diabetes 
Mellitus (TB-DM) was predominantly seen in Chinese race. The older age group (56-
65 yr) was highly affected with TB-DM, whereas TB-HIV and TB-Hepatitis was 
more in the sexually active age group. Patients with DM had a higher incidence of 
PTB (87.5%) and patients with HIV/AIDS had a higher incidence ofEPTB (26.1%) 
and PTB with EPTB (6.1%). The incidence rate ofTB in the prison was 440/100,000 
populations. The higher incidence rate (7551100,000 population) was seen in 
Selangor prisons. Majority of the patients (78.9%) in the study complained of cough 
as the symptom experienced. Culture sensitivity test was the most reliable laboratory 
test for diagnosis, as 70.6% ofthe patients responded positively. Of the 9337 patients 
in the present study, 7241 (77.6%) patients were successfully treated. The Odd Ratio 
(OR) of patients treated successfully in the hospital compared to those in the prison 
was 6.696. The treatment success rate was highest in PTB group patients (79.5%). 
When TB-DM, TB- HIV/AIDS and TB-Hepatitis cases were assessed, 73 .3%, 68.6% 
and 75.4% of patients were successfully treated respectively. The mortality rate was 
higher (23 .8%) in the TB-DM-HIV group of patients. The risk factors identified for 
higher mortality rate in this group of patients were increased age, alcohol 
consumption and Chinese race. 
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CHAPTER 1 
INTRODUCTION 
1.1 General Introduction and Historical Background ofTB 
Tuberculosis (TB) is one of the most dreadful diseases, accounting for the life of 
number of humans. This outrageous disease is caused by Mycobacterium tuberculosis 
(MTB). Even though evidence exist that this disease was prevalent in the pre-historical 
era, revolutionary changes took place only in 1888 when Robert Koch discovered 
Mycobacterium tuberculosis (Daniel, 2006). 
The genus Mycobacterium originated more than 150 million years ago (Hayman, 
1984). In East Africa early progenitor of Mycobacterium tuberculosis was present as early 
as 3 million years ago, and literature suggests that it may have infected early hominids 
prevalent at that time (Gutierrez et al. 2005). Previous studies suggested that all members 
of Mycobacterium tuberculosis complex are the clonal progeny of a single successful 
ancestor, resulting from an evolutionary tail back that occurred 15,000 to 20,000 years 
ago (Sreevatsan et al., 1997). 
All kinds of currently present Mycobacterium tuberculosis (MTB) pathogen are 
found in East Africa. However, the spreading causes vary around the globe (Gagneux, 
2006). Mycobacterium tuberculosis was detected in the DNA obtained from the tissues of 
Egyptian mummies roughly around 5400 years old. These findings further emphasize that 
TB was prevalent way back in the history. There are evidences describing the prevalence 
of tuberculosis in India and China 3300 and 2300 years ago respectively (Daniel, 2006). 
Archaeologist proved on the basis of archaeological evidence that tuberculosis was 
prevalent in America during rhe pre Columbian period (Arriaza et al. , 1995). Due to 
historical background and wide-spreading nature of tuberculosis, it was known by many 
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different names throughout the history like, King ' s Evil, Scrofula, Phthisis, White Plague 
etc. (Daniel, 1997; Daniel, 2006). 
Laennec, with the invention of the stethoscope, elucidated the pathogenesis of 
tuberculosis and unified the concept of the disease, whether pulmonary or extrapulmonary 
(Daniel, 2004). Hermann Heinrich Robert Koch (1882) changed the history of 
tuberculosis significantly (Daniel, 2005). The bacillus causing TB known as 
"Mycobacterium tuberculosis" was described first by him. Due to his legendry 
contributions to bacteriology, for illumination of the etiology of TB he was awarded the 
Noble Prize in Medicine or Physiology in 1905. In 1890s Robert Koch prepared 
tuberculin which was used for pre-symptomatic TB test later-on. 
In 1920's Assman introduced the theory of "Re-infection" (once treatment was 
completed the person gets infected again) which is still acceptable among doctors. Due to 
wide spreading nature of TB separate hospitals & clinics were used for treatment to save 
the life of coming generations. Such isolated treatment prevented the widespread of TB. 
There was a dramatic decrease in the mortality rates in the early and mid 19th century 
(Wilson, 1990). 
1.1.1 History ofTuberculosis Therapy 
Once it was assured that TB was an infectious disease, effective TB treatment 
methods were developed and in last 200 years, many new drugs have comming to 
existence. In the 18th century pulmonary collapse therapy was introduced by Italian 
physician Carlo Forlanini which was well accepted, especially for cavity closure, which 
modified into two other modes of treatment namely artificial and bilateral pneumothorax 
(Daniel, 1997). 
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Vaccine Development: 
With smallpox vaccine invention, researchers hoped to use a less virulent strain of 
M tuberculosis called M bovis, which is the bovine strain of tuberculosis to prepare the 
vaccine. From 1908 to 1919, Albert Calmette and Camille Guerin in France serially 
passed M bovis 230 times to result in a strain called Bacilli Calmette-Guerin, which was 
named as BCG vaccine. This vaccine was, for the first time, used in humans in 1921 and 
is still in use. However, A1. bovis was equally contagious in humans because of cattle to 
human transmission. 
Sanatoriums: 
For TB management many sanatoriums were opened in the 20th century for the 
treatment and isolation of tuberculosis patients. Initially, they were only open to the 
privileged class but later on they were open for the privileged and under privileged 
patients. With the discovery of streptomycin and isoniazid in the 1940s, many of the 
sanatoriums were closed. 
1.1.2 Chemotherapeutic History of Tuberculosis 
Mortality rates due to TB began to decline in the early and mid 19th century 
(Wilson, 1990). The explanation for this decline remains unknown. Improvement in the 
socio-economic conditions, healthier food and introduction of chemotherapy might have 
contributed to the decline. 
Even though chemotherapy against infectious diseases, usmg sulfonamide and 
penicillin, had been underway for several years, these molecules were ineffective against 
Mycobacterium tuberculosis. During World War II Para amino salicylic (PAS) and 
Thiosemicarbazone were discovered and in due course these were the first therapeutic 
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agents which showed efficacy in the treatment of tuberculosis (Ryan, 1992). Later in 
1944 another success story came into the limelight, when Selman A. Waksman, Albert 
Schatz, and Elizabeth Bugie reported that purified streptomycin isolated and purified 
from Streptomyces griseus, the first antibiotic and first bactericidal agent was effective 
against MTB (Schatz, 1944; Ryan, 1992). A rapid succession of anti-TB drugs were 
developed in the following years. These were important because with streptomycin 
monotherapy, resistant mutants began to appear with a few months, menacing the success 
of antibiotic therapy. However, in the later years it was demonstrated that this problem 
could be overcome with a combination of two or three drugs. 
1.2 Epidemiology 
1.2.1 Epidemiology of Tuberculosis 
It is believed that one among three is either infected with Mycobacterium 
tuberculosis or is at risk of developing the disease. According to WHO (2004a) global 
statistics on epidemiology of tuberculosis South East Asian region predominates and 
constitutes about 1.6 million cases followed by Africa and Western Pacific region, 
contributing to about 1.1 million cases. While, America and Europe accounted for 
250,000 cases each in the same year. The global estimate for epidemiology of 
tuberculosis for the year 2004 was 8.9 million new cases and 1.7 million deaths (WHO, 
2006). It was reported that the global incidence rate of tuberculosis was growing 
approximately 1.1% per year, and the number of new cases at 2.4% per year, while the 
number of deaths surpass the number of those caused by heart disease, cancer or any 
other infectious disease (WHO, 2004a) . Most cases of tuberculosis (5-6 million) were 
diagnosed in the people aged between 15-49 years. 1t was observed that occurrence ofTB 
was higher in male as compared to female. Furthem10re, more than 90% of all 
tuberculosis cases and deaths occurred in the developing countries (Bloom, 1992). 
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In the early 1940s and 1950s, Tuberculosis was leading disease in the list of 
causes for death in Malaysia and it has been reported that tuberculosis was among the top 
five communicable diseases (lyawoo, 2004). TB chemotherapy was available only in the 
late 1950s, when TB was the major cause of morbidity and mortality (MOH Malaysia, 
2002). National TB control programme was introduced in 1961 , and it played an 
important role in controlling TB across Malaysia. However in the last decade there has 
been a steady rise in the number of TB notifications in Malaysia. The incidence of TB in 
1997 was 63.6 per 100,000 populations as compared to 61.0 per 100,000 populations in 
1996 (MOH Malaysia, 1998). In the year 2000, total notified cases of TB were 15,057 
and the incidence rate per I 00,000 populations was 64. 7%. 
In Malaysia, highest disease burden was reported in Sabah followed by Wilayah 
Persekutuan, Sarawak and Pulau Pinang respectively (MOH Malaysia, 2000). Sabah 
accounted for about 29% or one third of the total new cases detected at national ievel and 
the annual notification rate were also the highest compared to other states in Malaysia 
(Jenarun et a/., 2003 ; Jiloris et a!., 2004). About I 0% of TB cases notified in Malaysia 
were discovered among the immigrant population (Iyawoo, 2004). Treatment success rate 
in term of completion of treatment was about 82%. On the other hand, the mortality rate 
steadily declined in the year 2000 from 14 deaths to 7 deaths per I 00,000 populations 
(Jiloris eta/. , 2004). WHO classified Malaysia as an 'intermediate ' TB burden country in 
2004a. In the last 20 years, the incidence rate has been stagnating although there was a 
slight upward trend between 2004 and 2006; from 60.3 to 62.6 per 100,000 (MOH 
Malaysia, 2006). 
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Malaysia for the first time implemented DOTS therapy in 1999, while WHO gives 
other measures in addition to DOTS such as organizing services close to the patient's 
home, considering patient's needs, and providing incentives in the form of free 
medications and monetary reimbursement. In Malaysia, medications are fully funded by 
the government. Charity organizations provide travel allowances and pocket money to the 
underprivileged patients. 
1.2.2 Epidemiology of Tuberculosis with HIV/AIDS 
AIDS (Acquired Immune Deficiency Syndrome) was thought to be a gay related 
immune deficiency syndrome. But later on, it was evident that sexual activity, 
contaminated needles, and blood products accounted for AIDS (Ford, 1992). 
Tuberculosis desolate HIV /AIDS patients and affects their progress badly. Nearly 
9.27 million people contracted TB in 2007; an increase of about 30,000 over the previous 
year (2006) was in line with the population growth. The above stated figures i.e. 9.27 
million also includes approximately 1.4 million people with HIV/AIDS as compared to 
estimated 0.6 million in 2006. In the year 2007 out of 1.75 million deaths, 0.456 million 
tuberculosis deaths were thought to be caused by HIV/AIDS. It means about one in four 
TB deaths are caused by TB with HIV/AIDS (WHO, 2009). HIV has killed over 20 
million people worldwide. Sub Saharan Africa accounts for I 0% of the total world 
population but almost 2/3 of the population has been reported to be suffering with HIV 
(UNAIDS, 2004). 
In Malaysia the first case of HIV/AIDS was identified in 1986, and in the year 
1999 HIV had an incidence rate of 20.80 per 100,000 populations, which increased to 
30.3 per 100,000 populations in the year 2002 and in the year 2003 the incidence rate was 
controlled to 26.9 per 100,000 populations (MOH, 2004). Over two-thirds of HIV/AIDS 
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cases are prevalent among intravenous drug users (IVDUs) and there has been 
exponential rise in the number of drug users reported globally (Friedland and Klein, 
1987). In Malaysia the prevalence of HIV among IVDUs remains disturbingly high; 
nearly 76% of all the HIV/AIDS cases reported between 1986 and 2000 were among 
IVDUs [Ministry ofHealth, (MOH) 2004]. In the early 1990s, incidence rate ofTB began 
to increase in USA and Western European countries (Raviglione et al. , 1993). Factors that 
were related to the increased rates include the human immunodeficiency virus (HIV) 
pandemic, homelessness and poverty, widening gap between rich and poor, increase in 
the number of refugees and the reduction of governmental support in prevention and 
treatment programmes (Brudney and Dobkin, 1991; Valadas and Antunes, 2005). 
For many years, the efforts to tackle TB and HIV/AIDS have been largely 
separate, despite · the overlapping epidemiology. However, it is now increasingly 
acknowledged that only through combined and co-ordinated efforts for both TB and 
HIV/AIDS can halt, this dual epidemic. According to WHO report (2009) out of 1.8 
million people who died from TB in 2008 worldwide, 0.5 million were infected with HIV, 
signifying the relation between the two deadly dangerous diseases . The H!V I AIDS 
epidemic is reviving an old problem in well resourced countries and worsening the 
existing problem of TB in less resourceful countries (Dye et a/. , 1999; Hausler et a!. , 
2006). 
1.2.3 Epidemiology of Tuberculosis with Diabetes Mellitus 
According to the International Diabetes Federation (IDF), there are currently 151 
million people in the age group 20 to 79 years with clinically diagnosed diabetics in 134 
countries. This accounts for an overall global prevalence of 4.6%. Most of these people 
have type II diabetes. Data confirmed that oral hypoglycemic agents are widely used to 
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control blood glucose levels, while significant number even uses insulin. Below the age of 
20 the predominant type of diabetes found is type I, which requires treatment with insulin 
after diagnosis. About 4.9 million people worldwide have type I diabetes under the age of 
20 according to IDF estimates (UKPDS, 1998). World Health Organization in 1998 has 
projected the prevalence of diabetes among adults worldwide will be more than double 
the existing, from 135 million to 300 million by the year 2025 (King et al. , 1998) . 
. TB has already been declared a "global emergency" by the WHO in 1992 and was 
recognized as a single biggest killer. Diabetes mellitus was also recognised as an 
independent risk factor for developing lower respiratory tract infections {Winterbauer et 
al. , 1969). The frequency of occurrence of TB increases in diabetics resulting in a 
significantly higher m0rtality rate (Root, 1934; Jabbar et al., 2006) . The incidence of 
diabetes as such appears to be higher among tuberculosis patients (Jeon and Murray, 
2008) as compared to the general population. Now, with diabetes assuming epidemic 
proportions with TB; it is vital to take measures for the prevention and control of this 
deadly combination. 
Similar to the world findings, there was a significant increase in the diabetes 
mellitus cases in the Malaysian population. The number has increased from 1.4 million in 
1998 to 1.8 million in 2002 (N issapatom et al. , 2005a) . 
1.2.4 Epidemiology of Multi Drug Resistant Tuberculosis (MDR-TB) 
Multi-drug resistant tuberculosis (MDR-TB) is defined as a tuberculosis that is 
resistant to at least isoniazid and rifampicin. The MDR-TB commonly develops in the 
course of TB treatment (Iseman, 1999). The inadequate use of resources, particularly the 
available treatment strategies has lead to a worrying level of MDR-TB in many regions of 
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the world. According to 2008b, WHO report 489131 cases of MDR-TB emerged in 2006 
and that the global proportion of MDR-TB among all the TB cases was 4.8%. India, 
China and Russian federation were estimated to have the highest number of MDR-TB 
cases. A total of 27 countries approximate for about 86% of the world MDR-TB cases 
were showing around the globe (WHO, 2008b; Wright et a/., 2009). As with TB, 99% 
MDR-TB cases are from resource poor countries. However due to global immigration, of 
people from resource poor countries to develop countries there will be an increase in the 
MDR-TB cases in the developed world in the near future (Ormerod, 2005). There were an 
estimated 500,000 cases of multidrug-resistant (MDR) tuberculosis in 2007 (including 
289,000 new cases); of these, 131,000 were in India, 112,000 in China, 43,000 in Russia, 
16,000 in South Africa, and 15,000 in Bangladesh; 55 countries had reported cases of 
extensively drug-resistant (XDR) tuberculosis by the end of 2008. These last figures are 
reason for considerable concern and highlight a potential threat to our ability to treat 
tuberculosis (Donald, 2009). 
The various risk factors identified for MDR-TB can be broadly divided into two 
categories, those factors that facilitate the selection of resistance in the community and 
the special conditions which make the people vulnerable to this resistance (Caminero, 
2010). The risk factors. under the first category include but are not limited to inadequate 
supply or poor quality of TB drugs, inadequate adherence to the treatment, social barrier, 
lack of money, poor infection control in health centers and hospitals, high prevalence of 
highly virulent MDR strains of MTB, HIV infection, non standardized treatment and non-
implementation of DOTS and DOTS expansion strategies (WHO, 2008b; Borrell and 
Gagneux, 2009; Migliori et a/. , 2009). The risk factors for the latter category include but 
are not limited to failure of the WHO category 11 TB drug regimen, chronic patients, 
contacts of MDR-TB cases, failure of WHO category J TB drug treatment regimen, 
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relapse and return cases, exposure at institutions reporting with high MDR-TB 
prevalence, residence in areas with high MDR-TB burden and usage of poor quality TB 
drugs (WHO, 2008b ). 
1.3 Tuberculosis among Prison inmates 
Different studies published as well as the WHO data shows that TB is a major 
problem among prison population. Prisoners are at a high risk for acquisition of MTB 
infection and development of TB infection compared to the general population due to 
overcrowding, closed living conditions, insufficient ventilation, generally low 
socioeconomic status, poor nutrition and poor health of prison inmates, delay test findings 
and inadequate therapeutic intervention (Coninx, 1995; Aerts, 2000). There is increasing 
recognition that the high risk of TB infection in prisons poses a problem not only for 
those who are in prison bm also for the society at large (Coninx, 2000). 
TB incidence can also be related to the length of incarceration (Bellin et a/. , 1993). 
Transmission patterns are generally difficult to establish, and the rate of unrecognized 
transmission may be quite high (Jones et a!., 1999; Mac Intyre et al., 1999). Above all , 
strains isolated in these settings are often Multidrug resistant (MDR) (Valway et a!., 
1994; Coninx et a/., 1998). Moreover, a high rate of MDR-TB (lip to 33%) has been 
observed in several prisons both in developed and developing countries (Va!way et a/., 
1994; Toungoussova et a/. , 2003) . The mortality rate among TB cases reached around 
24% in some prisons and in some TB accounts tor 50% of the overall prison deaths, 
worldwide, 10-100 time higher rates have been reported for TB in prisons than in local 
civilian population (WHO, 2000). 
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In the Selangor state, TB I HIV co-infection cases raised from 52 in 1998 to 13 7 in 
2002. Most of these cases were reported from the prisons and drug rehabilitation centers 
(DRC). The rate of positive TB I HIV co-infection was found to be 12-15 % in prison I 
DRC in the period 2000 to 2002 (Venugopalan, 2004). 
1.4 PATHOPHYSIOLOGY OF TUBERCULOSIS 
1.4.1 Causative Organism 
Tuberculosis is caused by the rod shape, non-spore forming, aerobic, non-motile 
Mycobacterium tuberculosis (Kathleen and Arther, 2002). Mycobacteria are around 0.5 x 
0.2 Jlm in size, classified as acid fast bacilli with a distinctive cell wall structure. The cell 
wall contains a substantial amount of mycolic acid a fatty acid, covalently attached to the 
polysaccharide arabinogalactan by peptidoglycan linkages to provide an unusual lipid 
barrier. This unusual barrier is the one responsible for resistance to antibiotic and the post 
defence mechanisms. This organism is an obligatory aerobe that grows most successfully 
in human tissues having the highest partial pressure of oxygen, such as the lung, renal 
parenchyma and growing ends of bones (Peloquin and Berning, 1994 ). The other 
important characteristic of bacteria includes slow growth. The presence of 
lipoarabinomannan, a carbohydrate structural antigen on the outside of the organism, 
which is immunogenic, allows the organism to survive after engulfment by the 
macrophages in human (Knechel, 2009). 
1.4.2 Pathogenesis 
Mycobacterium tuberculosis is spread by airborne droplets transmitted by 
coughing, sneezing, talking or singing of a person with TB. Once the droplet is inhaled it 
settles through the air passage. The majority of the bacilli are entrapped by the mucus 
secretion present in the upper respiratory system (Frieden et a/., 2003). The baciiii 
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entrapped are driven out along with the mucus by the cilia present on the surface of the 
mucus producing goblet cells. This is the primary defensive mechanism that prevents 
occurrence of TB in most persons (Jensen eta/., 2005). In few persons when the bacilli 
bypass the ciliary diverge, they reach the aiveoli and are engulfed by alveolus 
macrophages. The subsequent phagocytosis by macrophages initiates a series of events 
that may result in either complete bacilli destruction or progression into latent TB or 
progressive to active TB (Frieden et al., 2003). The series of events are determined by the 
quality of host defence and the invading mycobacterium (Goyot-Revol eta/. , 2006). 
After being ingested by the macrophages the bacillus multiplies slowly (Frieden et 
a/. , 2003). At the same time proteolytic enzymes and cytokines are produced by the 
macrophage to destroy the bacilli (Nicod, 2007). The cytokines so produced drags the T-
Lymphocytes to the site. At this stage the macrophage surface bound bacilli antigen is 
presented to the T eel! (Nicod, 2007). This process continue for a period of2 to 12 weeks 
until a sufficient number of micro organisms grow to fully bring forth the T cells 
mediated immune response (Frieden eta/., 2003). 
In patients with intact cell mediated immunity, the next stage is formation of a 
nodular type lesion known as granulomas surrounding the bacilli (Rosenkrands et a/., 
2002). These lesions are formed as a result of accumulation of activated T lymphocytes 
and macrophages. The lesion environment limits the growth and multiplication and 
spread of the bacilli. The macrophages are destroyed in this environment and a solid 
necrosis is formed at the centre of the lesion. However, the bacilli adapt to the conditions 
and survive by changing their protein regulaiion (Li eta!., 2002; Dheda eta/., 2005). 
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After 2 to 3 weeks, the necrosis is called as caseous necrosis and is characterised 
with low oxygen levels, low pH and limited nutrition. These conditions restrict the growth 
further and the disease goes into the latent phase. In a person with ample immunity the 
necrosis undergoes fibrosis and calcification. This brings about successfully controlling 
the infection (Dheda et a/. , 2005). In persons with weak immune system it progress to 
primary progressive tuberculosis (Li et a/ .. 2002) . In these persons the granuloma 
formation is initiated but it is inefficient in containing the bacilli. The necrotic tissue 
undergoes liquefaction and then the fibrous cell wall loses its integrity and drains the semi 
liquid necrotic material into bronchus and blood vessels further spreading the bacilli 
(Dheda eta/., 2005). 
1.4.3 Drug Resistance Mycobacterium tuberculosis 
Drug resistance TB is not a new phenomenon. !t came into picture when M 
tuberculosis strains that were resistant to streptomycin emerged immediately after 
discovery and introduction of streptomycin for the treatment of TB in 1944. Genetic 
resistance to an anti- TB drug is due to chromosomal mutations at a lower frequency . 
Even though the frequency of chromosomal mutations is low drug resistance is reaching 
alarming proportions at a greater speed due to the amplification ofthe mutations through 
human error (Zhang and Yew, 2009). The human errors include monotherapy due to 
irregular drug supply, inappropriate doctor prescription and in most cases it is poor 
patient adherence to the treatment. The subsequent transmission of this genetically 
modified strain to other individuals greatly intensified the problem. The drug resistance is 
currently classified by categorizing drug resistance in new cases and previously treated 
cases ofTB in which the treatment lasts for at least one month (WHO, 2008b). 
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1.5 TRANSMISSION OF DISEASES 
1.5.1 Tuberculosis 
Tubercle bacilli are transmitted through the air by aerosolized droplet nuclei that 
are produced when a person with pulmonary or laryngeal TB coughs, sneezes, speaks or 
sings. This droplet nuclei, which contain one of three M tuberculosis organisms, are 
small enough (I to 5 11m) tc remain suspended in the air for long periods of time and to 
reach the alveoli within the lungs when inhaled. Tubercle bacilli are not transmitted 
through inanimate objects (Knechel, 2009). 
The factors that influence the likelihood of transmission of Mtuberculosis, 
include the number of organisms expelled into the air, the concentration of organisms in 
the air, duration of the exposure, and the immune system of the exposed individual. 
Family household contacts especially children, hospital, nursing homes, prisons such 
people are significantly on high risk to become infected. Individuals with HIV I AIDS or 
transplant patients are thought to be more likely to become infected with Mtuberculosis 
after exposure then normal immune function (American Thoracic Society, 2000). 
Several techniques are effective in limiting airborne transmission of M 
tuberculosis such as adequate room ventilation, where 6 or more air exchange per hour is 
desirable (American Thoracic Society, 2000), ultra violet radiation, coughing patient used 
masks and treating patient with effective anti-tuberculosis therapy. 
1.5.2 Human Immunodeficiency Virus (HIV) 
Skin of healthy individual does not allow HIV to get into the body. In fact H!V 
can enter into the body through an open cut or sore, or through contact with the mucous 
membranes. Transmission risk is very high when HIV comes in contact with the more 
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porous mucous membranes in the genitals, the anus, and the rectum, which are inefficient 
barriers to HIV. Transmission is also possible through oral sex because body fluids can 
enter the bloodstream through cuts in the mouth, but chances are low due to low 
concentration of body secretions. There are several modes of transmission that have been 
identified : 
1. Unprotected vaginal, anal and oral sex. 
2. Direct blood contact, which may occur through needle sharing, transfusions, 
accidents in health care settings, or certain blood products. 
3. Mother to baby; before or during birth or through breast milk. 
4. Sharing syringes (Needles) to inject illegal drugs or medicine can pass blood 
directly from one person's blood stream to another's . It is a very efficient way to 
transmit HIV and other blood borne viruses such as Hepatitis B (HBV) and 
Hepatitis C (HCV). 
5. HIV/ AIDS prevention depends on the interception of transmission and can be 
prevented by avoiding needle sharing, sex with exposed person. The main means 
of prevention includes coverage of condoms during sexual intercourse (Baron et 
a!. , 1994 ). 
1.6 CLINICAL MANIFESTATION OF TUBERCULOSIS Moll> ITS CO-
MORBID CONDITIONS: 
1.6.1 Tuberculosis 
1.6.1(a) Pulmonary Tuberculosis 
Based on the immune system of the patient, tuberculosis might develop differently 
in each patient. The various stages include latency, primary TB, primary progressive TB 
and extra pulmonary TB (EPTB). The clinical manifestations of the first three stages are 
given in Appendix I (Knechel, 2009). Approximately I 0% of individuals who acquire TB 
infection and do not receive therapy for the latent infection will develop active TB. The 
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risk of developing active disease is highest in the first 2 years of infection (American 
Thoracic Society, 2000). Physical or emotional stress can destroy balance between the 
immune system and the infection, leading to active disease. The ability of the host to 
respond to the organism may also be reduced by certain diseases such as diabetes 
mellitus, silicosis, diseases associated with immunosuppressant (HIV/AIDS, person on 
corticosteroids and immunosuppressive agent treatment). The likelihood of developing 
active TB disease is greater in persons with these diseases (Barnes et al., 1991; American 
Thoracic Society, 2000). HIV infected persons, especially with low T cell counts, develop 
active TB disease rapidly after becoming infected with M Tuberculosis up to 50% of 
these individuals may develop active disease in the first two years after · infection (Daley 
et a/., 1992). Other factors also contribute to the development of active disease like 
gastrectomy, intestinal bypass surgery, intravenous drug user (IVDU). Children's Jess 
than 2 years of age may also be at an increased risk of developing active TB (American 
Thoracic Society, 1990; American Thoracic Society, 2000). 
1.6.l(b) Extra Pulmonary Tuberculosis 
Tuberculosis of organs other than the lungs is called extra pulmonary 
tuberculosis. EPTB includes the pleura (TB pleurisy), peripheral lymph nodes, abdomen, 
genito-urinary tract, skin, joints and bones, and the brain (MOH, Malaysia 2002). The 
most serious cases are when TB is found in the central nervous system where the 
infection can lead to tuberculomas or meningitis. If left untreated, meningitis may be 
fatal. People with frequent headache and changes in mental status after possible exposure 
to the organism should go for diagnosis. Another lethal form is infection of the blood 
stream with Mycobacterium tuberculosis causing military TB. Lymphatic TB is the most 
common EPTB. 
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The incidence of EPTB decreases with age. However the incidence increases in 
geriatric population. In the past AIDS era in USA, I 008 patients with extra pulmonary 
tuberculosis were older than 65 years. Two thirds of 4 million infected people with both 
HIV and TB were diagnosed to have extra pulmonary tuberculosis. 
Different types of EPTB have been reported which shows different types of 
clinical sign and symptoms like, Miliary TB were constitutional symptoms (fevers, chills, 
sweats) and diagnosed by chest X-ray, symptoms of gastrointestinal TB at presentation 
included (weight loss, fever and abdominal distention), and common symptoms of spinal 
TB included fever, progressive lower extremity weakness or paraplegia; and back pain, 
while diagnosed by radiographic evidence (X-ray, CT, or MRI) etc (Fader eta/. , 201 0). 
1.6.2 HIV 
Early sign and symptoms of HIV infection are variable. Generally the sign and 
symptoms range from mild non-specific fatigue and malaise to fever, night sweats and 
weight loss (Miedzinski, 1992). The Centers for disease control has classified HIV 
infection into various groups as discussed below: (CDC, 1986) 
Group 1: Acute HIV infection: 
Patients who within one month of exposure develop the first clinical evidence of 
HIV infection, which may appear as an acute retroviral syndrome fall under this group. 
This is a mononucleosis-like syndrome with symptoms including fever, rash, diarrhea, 
lymphadenopathy, myalgia, arthralgia, and fatigue. Development of antibodies usually 
follows. 
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Group II: Asymptomatic HIV infection: 
A group in which, most persons develop antibodies to the HIV within 6 to 12 
weeks after exposure. Although individuals may remain asymptomatic for months or 
years, they can transmit the virus. 
Group III: Persistent generalized lymphadenopathy: 
A group in which, most patients develops persistent generalized lymphadenopathy 
that lasts longer than 3 months. 
Group IV: illY-associated diseases 
A group, who is clinically variable and has signs and symptoms of HIV infection 
other than or in adqition to lymphadenopathy, based on clinical findings, patients in 
Group IV may be assigned to one or more of the following subgroups: (A) constitutional 
disease, also known as wasting syndrome. This subgroup is characterized by fever that 
lasts more than one month, involuntary weight loss of greater than I 0% for baseline, or 
diarrhea persisting for more than one month, (B) neurological disease, (C) secondary 
infectious disease, (D) secondary cancers, and (E) other conditions resulting from HIV 
infections. 
1.6.3 Diabetes Mellitus 
It's not unusual to have diabetes mellitus (OM) and yet have no symptoms. Type 2 
diabetes, in particular, develops slowly. Many people have type 2 diabetes for as long as 
eight years before its being diagnosed. When symptoms do develop, they often vary. But 
tvm symptoms that occur in most of the people with the disease are increased thirst and 
increase in the frequency of urination (CDC, 2004) . Other signs and symptoms of DM 
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include extreme hunger, increased fatigue, irritability, unusual weight loss, blurred vision, 
slow-healing sores or frequent infections and neuropathy (Clark et al., 2007). 
1.6.4 TB/HIV Co-Infection 
In an individual infected with both M tuberculosis and HlV, TB couid develop at 
any stage in the course of the HIV infection. The clinical presentation of tuberculosis in 
HIV infected patients varies depending on the severity of immunosuppression. Clinical 
presentation of tuberculosis in persons with early HIY infection has been found to be 
similar to that observed in persons with strong immune system and HIV -negative patients 
(Zumla et al. , 2000). 
In HIV -positive patients the pathologic and clinical features of TB varies with the 
patient's CD4 lymphocyte count. Expression of TB is dependent on the stage of HIV 
infection as measured by CD4 counts. Patients with HIV and relatively good CD4 cell 
counts (> 250 cells/cubic mm) have TB similar to HIV negative persons while those with 
lower CD4 cell counts have atypical presentation. When the CD4 counts are greater than 
200cells/mm3, the patient's most often or not suffer with pulmonary TB. The 
manifestation of pulmonary TB includes infiltrates and cavitations in the apical posterior 
segments of the upper lobe and the superior segment ofthe lower lobe of the lungs as read 
radiologically and pleura effusions are common (Perlman et a/. , I 997). As the level of 
immunosuppression increases and CD4 cell count decreases the presentation of the 
disease beccmes atypical with interstitial non-cavitary lesions because ofpoor granuloma 
formation and these involve more of the lower lung fields as read radiologically. As the 
CD4 counts further fall extra pulmonary TB is more likely to occur with positive blood 
cultures forM. tuberculosis (Perlman et al. , 1997; Saltini, 1999). Furthermore, when CD4 
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cell count is greater than 200 and less than 500, reactivation of tuberculosis can occur in 
HIV infected individuals (Bhatia, 2001; Chan eta/., 201 0). 
In HIV negative patients, pulmonary tuberculosis is the most common form of 
tuberculosis observed and it accounts for about 80% of the total TB cases. In contrast in 
HIV positive patients, only 20% of the population is with pulmonary TB, while 53-62% 
of cases are with extra pulmonary TB (FitzGerald and Houston, 1999). The most common 
extra pulmonary site is the lymph node. However, neurological, pleural, pericardia!, 
abdominal and virtually every-body site can be involved in HIV positive patients (Chan et 
al. ; 201 0). 
HIV infected patients with dormant, previously contained loci of infection, 
eventually develop reactivation TB because of the gradual loss of cell-mediated 
immunity. Reactivation TB occurs early in the course of immune depression in HIV 
infected individuals. These cases are pathologically characterized by the formation of 
"hard" nodules with epitheloid cell granulomas, little caseous necrosis and few bacilli . 
Cavitation may also occur as an expression of typical reactivation of disease. In more 
advance stages of the HIV infection, the pathology is characterized by military acinar 
nodules composed of aggregates of macrophages with scanty lymphocyte reaction, little 
granuloma formation, marked necrosis and numerous extracellular bacilli (Saltini, 1999). 
The presence of HIV co-infection may alter the radiologic findings in pulmonary 
TB (Long et a/., 1991 ). From the radiological findings it can be observed that in these 
patients the involvement of lower lobe of the lung is prominent, pleural effusion is more 
common; cavities are less common and intrathoracic adenopathies is evident (Long eta/., 
199 j). 
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1.7 DIAGNOSIS 
1.7.1 HIV/AIDS 
The diagnosis of HIV infection is generally achieved through antibody detection 
with serologic tests. The test which is used in general is ELISA (enzyme-linked 
immunosorbent assay) (Kassu, 2007). In Malaysia, ELISA and the particle agglutination 
(PA) are used as diagnostic tests for HJV/AIDS. The initial screening is done using the 
ELISA test at the screening centers, incase ELISA test is positive then it is further 
verified and confinned by using PA test. Clinical specimens from individuals in high-risk 
groups (lVDUs and sexual ly wanton) are confirmed locally using ELISA test. 
An individual is declared as "Diagnosed Case of AIDS", following clinical 
definitions outlined below according to WHO, 200 I; 
~ A positive test for HIV antibodies by the ELISA and or Particle Agglutination 
test(s), or a positive supplementary test. 
~ A CD4 T cell lymphocyte count of less than 2001-!L. 
);- The presence of an AIDS indicator disease like Pneumocystis carinii pneumonia, 
Karposi 's sarcoma, tuberculosis (pulmonary or extrapulmonary), toxoplasmosis of 
the brain and other serious opportunistic infections (Kumarasamy eta/. , 2003). 
1. 7.2 Diabetes Mellitus 
On the basis of clinical sign and symptoms following laboratory test are 
performed for diagnosis purposes: 
~ A random blood glucose ~ 200mg I dL 
~ A fasting blood glucose (FBG) ~ 126 mg I dL 
Many factors can impair blood glucose level ; these all factors must be excluded 
before a diagnosis of diabetes is made. Some acute illness (myocardial infarction), 
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pregnancy, stress, drug and other chemical may falsely elevate the plasma glucose 
concentrations (American Diabetes Association (ADA), 2003). 
1. 7.3 Tuberculosis 
1.7.3 (a) Tuberculin Skin Test (TST) 
Tuberculin Skin Test (TST) is the widely used laboratory test to identify patients 
actively infected with tuberculosis and for those with latent TB as well. There are 
different types of tuberculin skin test reported but the most commonly used one is 
Mantoux test. In this test procedure graded doses of tuberculin are injected intradermally 
on the forearm using a tuberculin syringe. Tuberculin is a Purified Protein Derivative 
(PPD), which is a collection of mixed proteins and other materials filtered from killed M 
tuberculosis cultures. The test works on basic principle, that ifthe body has been exposed 
to infection with TB it will recognise the proteins and mount an immune response to it. 
This response would be expressed in the form of a lump, swelling or blister at the site of 
injection, revealing that the person is infected. Unfortunately, the skin test has a poor 
sensitivity and specificity (Deek et a/., 2003). The sensitivity of the test is low if the 
person being tested has had the BCG vaccination earlier in life or if they have a deprived 
immune system (immunocompromised) due to other illness or medical treatment and 
even some time shows false positive results (Ferrara et a/., 2005). On the forearm 0.1 ml 
of the 5 TU of PPD is injected intradermally. On examination after 48-72 hours a positive 
reaction is indicated by erythema and indurations of > 10 mm size (MOH Malaysia, 
2002). 
1.7.3 (b) Sputum Smear Microscopy (SSM) 
Sputum smear microscopy (SSM) has been the first diagnostic test that has been 
used to screen for active PTB. SSM is based on the principle of Ziehl Neelson diagnostic 
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technique of direct smear microscopy of sputum (Koch and Cote, 1965). The umque 
properties of bacterial cell wall of Mycobacterium tuberculosis allow it to retain the 
primary stain of carbol fuchsin and methylene even after exposure to strong acid 
solutions, they are called acid-fast bacilli. In the Ziehl Neelson staining proct!dure, using 
carbo! fuchsin and methylene blue, the acid-fast organisms appear pink or red under the 
microscope (Aggarwal , 2006). 
Despite being widely used, microscopy has limitations as it is not specific for the 
detection of acid-fast bacilli (AFB) in sputum and can only detect AFB in 60-70% of 
culture positive specimens (Steingart et a!. , 2006; Perkins and Cunningham, 2007). In 
contrast to old practices for detection of PTB, some new studies concluded that the 
examination of two sputum sample should be used to confirm TB (Leonard eta/., 2005). 
1.7.3 (c) Culture 
Cell culture techniques are the widely used methods to identify M tuberculosis, 
pulmonary or extra-pulmonary. By assessing the effect of antibiotics on the cultured 
bacteria, this technique can also provide data on likely effectiveness of certain antibiotics. 
However, it is not always possible to obtain bacteria in the sample, especially in non-
pulmonary TB and the test is therefore not always reliable. A drawback of this method is 
the time awaited to get the results, which can be anything in between six to eight weeks 
(Singh, 2006). However, rapid and more sensitive diagnostic methods are also available 
like Bactec, Polymerase chain reaction (PCR) but these are relatively expensive and are 
not available in all the diagnostic centres (Saiki, 1985). 
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1.7.3 (d) Chest X-ray 
Chest x-ray is an important diagnostic tool for the physician, to check for lung 
abnormalities in people who have symptoms of TB disease. However the chest X-ray 
cannot confirm active TB, especially if the infection is not in the lungs or may be smear 
negative (Davis, 20 I 0). The chest X-ray also has a poor ability to detect infection in the 
early stages of disease. The damage to the lungs may not yet have become sufficiently 
marked to be detectable by chest X-ray and thus people who have active TB can be 
missed including elderly and or HIV /AIDS patients (Knechel, 2009). Furthermore, 
scarring in the lungs remains after a previous TB disease even if the patient is completely 
cured and therefore it is difficult to distinguish past cured TB from current active disease. 
1.7.4 Extra Pulmonary Tuberculosis 
Diagnosis of EPTB is often difficult. A negative smear of acid-fast bacilli and 
failure to culture the bacilli contributed to ineffective EPTB diagnosis (Marjoriep, 2005). 
The recognition and understanding of the radiographic findings in the EPTB case may 
reduce the difficulty faced EPTB diagnosis (Engin eta/., 2002). The diagnosis of EPTB is 
often difficult as compared to pulmonary TB due to the low sensitivity of the usual 
diagnosis methods for the disease (AFB smear, Mantoux, culture and chest radiography 
tests). The sensitivity of the most commonly used methods range from 25%- 39% (Marco 
e: al,. 1998). 
1.7.4 (a) Tuberculosis Lymphadenitis 
Tuberculosis lymphadenitis is the most common type of extra pulmonary 
tuberculosis. Lymphatic TB was known as scrofula and later-on was known as the king ' s 
evil (Grzybowski and Allen, 1995). It can be diagnosed by fine needle aspiration (FNA) 
of giands (lymph nodes glands). This type of specimen is submitted for AFB test and 
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